MCTS1: A Potential Drug Target Or Biomarker in Cancer Research
MCTS1: A Potential Drug Target Or Biomarker in Cancer Research
Multiple copy in T-cell lymphoma-1 (MCTS1) is a gene that has been identified as a potential drug target or biomarker in the field of cancer research. MCTS1 is a gene that is located on chromosome 6 and has been shown to be involved in the development and progression of T-cell lymphomas.
Research has shown that MCTS1 is highly expressed in T-cell lymphomas, and that it is associated with poor prognosis in patients with these types of cancer. MCTS1 has also been shown to be involved in the development of a type of T-cell lymphoma called Castleman disease, which is characterized by lymph node enlargement and systemic symptoms.
One of the key challenges in researching MCTS1 is its involvement in the development and progression of cancer. MCTS1 is expressed in most types of T-cell lymphomas, but its role in the development of these conditions is not well understood.
One possible way to study the role of MCTS1 in cancer is to use techniques such as RNA interference or gene editing to knock down or activate the MCTS1 gene. This would allow researchers to study the effects of MCTS1 on the development and progression of cancer.
Another approach to studying MCTS1 is to use it as a biomarker to predict the outcomes of cancer treatments. For example, researchers could use MCTS1 as a biomarker to identify patients who are at high risk of recurrence after a cancer treatment. This could help doctors to tailor their treatments to minimize the risk of recurrence and improve the overall quality of life for patients.
In addition to its potential as a drug target or biomarker, MCTS1 is also of interest to researchers because of its association with the development of Castleman disease. This suggests that MCTS1 may be a useful target for new treatments for this type of cancer.
Overall, MCTS1 is a gene that has the potential to be a drug target or biomarker in the field of cancer research. Further studies are needed to fully understand its role in the development and progression of T-cell lymphomas, as well as its potential as a biomarker for cancer treatments.
Protein Name: MCTS1 Re-initiation And Release Factor
Functions: Anti-oncogene that plays a role in cell cycle regulation; decreases cell doubling time and anchorage-dependent growth; shortens the duration of G1 transit time and G1/S transition. When constitutively expressed, increases CDK4 and CDK6 kinases activity and CCND1/cyclin D1 protein level, as well as G1 cyclin/CDK complex formation. Involved in translation initiation; promotes recruitment of aminoacetyled initiator tRNA to P site of 40S ribosomes. Can promote release of deacylated tRNA and mRNA from recycled 40S subunits following ABCE1-mediated dissociation of post-termination ribosomal complexes into subunits. Plays a role as translation enhancer; recruits the density-regulated protein/DENR and binds to the cap complex of the 5'-terminus of mRNAs, subsequently altering the mRNA translation profile; up-regulates protein levels of BCL2L2, TFDP1, MRE11, CCND1 and E2F1, while mRNA levels remains constant. Hyperactivates DNA damage signaling pathway; increased gamma-irradiation-induced phosphorylation of histone H2AX, and induces damage foci formation. Increases the overall number of chromosomal abnormalities such as larger chromosomes formation and multiple chromosomal fusions when overexpressed in gamma-irradiated cells. May play a role in promoting lymphoid tumor development: lymphoid cell lines overexpressing MCTS1 exhibit increased growth rates and display increased protection against apoptosis. May contribute to the pathogenesis and progression of breast cancer via promotion of angiogenesis through the decline of inhibitory THBS1/thrombospondin-1, and inhibition of apoptosis. Involved in the process of proteasome degradation to down-regulate Tumor suppressor p53/TP53 in breast cancer cell; Positively regulates phosphorylation of MAPK1 and MAPK3. Involved in translation initiation; promotes aminoacetyled initiator tRNA to P site of 40S ribosomes. Can promote release of deacylated tRNA and mRNA from recycled 40S subunits following ABCE1-mediated dissociation of post-termination ribosomal complexes into subunits
The "MCTS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MCTS1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MCTS2 | MCU | MCUB | MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27 | MED28 | MED29 | MED30 | MED31 | MED4 | MED4-AS1 | MED6 | MED7 | MED8 | MED9 | MEDAG | Mediator Complex | Mediator of RNA Polymerase II Transcription | MEF2A | MEF2B | MEF2C | MEF2C-AS1 | MEF2C-AS2 | MEF2D | MEFV | MEG3 | MEG8 | MEG9 | MEGF10 | MEGF11 | MEGF6 | MEGF8 | MEGF9 | MEI1 | MEI4 | MEIG1 | MEIKIN | MEIOB | MEIOC | MEIOSIN | MEIS1 | MEIS1-AS2 | MEIS1-AS3 | MEIS2 | MEIS3 | MEIS3P1 | MEIS3P2 | Melanin | Melanin-concentrating hormone (MCH) receptor | Melanocortin receptor
